Cargando…
Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L
Neuroblastoma is the most common extracranial solid tumor during infancy and childhood. Outcome of high-risk and late-stage disease remains poor despite intensive treatment regimens. Suppressing inhibitor of apoptosis proteins (IAPs) using Smac mimetics (SM) significantly sensitizes neuroblastoma (N...
Autores principales: | Najem, Safiullah, Langemann, Doerte, Appl, Birgit, Trochimiuk, Magdalena, Hundsdoerfer, Patrick, Reinshagen, Konrad, Eschenburg, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341933/ https://www.ncbi.nlm.nih.gov/pubmed/27655666 http://dx.doi.org/10.18632/oncotarget.12055 |
Ejemplares similares
-
Sensitization of neuroblastoma for vincristine-induced apoptosis by Smac mimetic LCL161 is attended by G2 cell cycle arrest but is independent of NFκB, RIP1 and TNF-α
por: Langemann, Doerte, et al.
Publicado: (2017) -
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice
por: Shekhar, Tanmay M., et al.
Publicado: (2019) -
Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
por: Wang, Jingqiu, et al.
Publicado: (2020) -
The SMAC mimetic LCL-161 selectively targets JAK2(V617F) mutant cells
por: Craver, Brianna M., et al.
Publicado: (2020) -
The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock
por: West, A C, et al.
Publicado: (2016)